Boehringer Ingelheim is investing $217 million to upgrade and expand its Fremont, CA manufacturing facility. This investment will add nearly 300 skilled positions in the area. The site was recently awarded $25.5 million in two separate tax credits from the state, making them the largest award to a pharmaceutical company. The expansion will allow the company to increase its manufacturing capacity by one-third.
 
“The Bay Area is the largest biotech cluster in the world. We are happy to have made Fremont our home and are grateful for the support we have received from the community and the State of California,” said Jens Vogel, president and chief executive officer of Boehringer Ingelheim Fremont, Inc. “We have made a commitment to the region and are excited to continue to invest in the Bay Area and expand our workforce to help increase patient access to high-quality medicines.” 
 
Boehringer’s Fremont facility focuses on manufacturing medicines for immunology, rheumatology and oncology.